Christopher Degnan
Chief Financial Officer
CFO
CFO
Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Galera Therapeutics, Inc. (GRTXD) | Chief Financial Officer | $432,250 | $834,865 |
| 2021 | Galera Therapeutics, Inc. (GRTXD) | Chief Financial Officer | $395,833 | $1,273,545 |
| 2020 | Galera Therapeutics, Inc. (GRTXD) | Chief Financial Officer | $380,000 | $1,458,593 |
| 2019 | Galera Therapeutics, Inc. (GRTXD) | Chief Financial Officer | $76,487 | $2,229,086 |
| 2018 | Galera Therapeutics, Inc. (GRTXD) | Chief Financial Officer | — | — |
Executive changes
- 2024-10-08
- 2024-10-08
-
Terminated Chief Financial Officer and principal financial officer at Galera Therapeutics, Inc. (GRTXD)2024-08-31
Earnings-call appearances
-
UroGen Pharma Ltd. Q4 FY2025 Earnings Call2026-03-02
UroGen Pharma Ltd. (URGN)
-
UroGen Pharma Ltd. Q3 FY2025 Earnings Call2025-11-06
UroGen Pharma Ltd. (URGN)